HALO - Halozyme Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue316,613146,691135,057
Cost of Revenue31,15233,20629,245
Gross Profit285,461113,485105,812
Operating Expenses
Research Development150,643150,84293,236
Selling General and Administrative53,81645,85340,028
Non Recurring---
Total Operating Expenses---
Operating Income or Loss81,002-83,210-27,452
Income from Continuing Operations
Total Other Income/Expenses Net2,5921,326422
Earnings Before Interest and Taxes83,594-81,884-27,030
Interest Expense21,98419,9775,201
Income Before Tax61,610-101,861-32,231
Income Tax Expense-1,3611,162-
Minority Interest---
Net Income From Continuing Ops62,971-103,023-32,231
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income62,971-103,023-32,231
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares62,971-103,023-32,231